Clinical Trial Update: Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating propranolol in combination with pembrolizumab and standard chemotherapy for unresectable or metastatic esophageal and gastroes…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Propranolol (propranolol)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Phase 2 | Status: RECRUITING